- May 26, 2013
- 01:19 AM CET
- search
- T&C's
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2013 EVOTEC
- Loading...
Top Story
Evotec and Harvard University to collaborate on development of new class of antibacterials
*TARGET PGB (PEPTIDOGLYCAN BIOSYNTHESIS) IS THE FOCUS OF COLLABORATION
DESIGNED TO DEVELOP NOVEL FAMILY OF ANTIBACTERIAL DRUGS BASED ON HIGHLY
VALIDATED TARGET
Hamburg, Germany and Cambridge, MA - 16 May 2013: Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.
Evotec Q1 2013: Driving Innovation Efficiency
- STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY - EVOTEC'S DRUG DISCOVERY PLATFORM GENERATES GROWTH
- NEW HORMONE IDENTIFIED AS PART OF THE CUREBETA INITIATIVE
- GUIDANCE 2013 CONFIRMED
Hamburg, Germany - 14 May 2013: Evotec AG today reported financial results and corporate updates for the first quarter of 2013.
- read moreDana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology
Hamburg, Germany and Boston, MA - 30 April 2013: The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.
- read more
Loading weather report...
Events
Jun 10, 2013 - 14th Annual Drug Discovery & Drug Development Leaders Summit 2013
Jun 03, 2013 - Jefferies 2013 Global Healthcare Conference
Company Presentation May
Building integrated and high value drug discovery alliances
2013-05_Evotec_Company presentation
Want to read some older articles?
- visit the archive